Related Experiment Videos

Primary stroke prevention and hypertension treatment: which is the first-line strategy?

Roberta Ravenni1, Joe F Jabre, Edoardo Casiglia

  • 1Department of Neuroscience, Santa Maria della Misericordia Hospital, Rovigo, Italy;

Neurology International
|November 5, 2011
PubMed

Insights

Lowering blood pressure (BP) with antihypertensive drugs reduces stroke risk. Different drug classes offer varying benefits, and combination therapy is logical. Fixed-dose combinations may improve BP control, but trials are needed to confirm stroke prevention efficacy.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Pharmacology

Background:

  • Hypertension (HT) is a primary vascular risk factor for stroke.
  • Antihypertensive treatments reduce stroke risk, but benefits vary by drug class.
  • Current guidelines recommend specific BP goals for stroke prevention.

Purpose of the Study:

  • To review the role of different antihypertensive agents in stroke risk reduction.
  • To evaluate the rationale for combination therapy in managing hypertension.
  • To discuss the potential of fixed-dose combinations (FDCs) for improving BP control and stroke prevention.

Main Methods:

  • Literature review of extensive evidence on antihypertensive agents and stroke risk.
  • Analysis of current guidelines for hypertension management in primary stroke prevention.
  • Discussion of the implications of newly available fixed-dose combinations (FDCs).

Main Results:

  • Angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), dihydropyridine calcium channel blockers (CCB), and thiazide diuretics have demonstrated stroke risk reduction.
  • Combination therapy using these classes is a logical approach for achieving BP goals.
  • A significant portion of the population remains undiagnosed or undertreated for HT, posing a high stroke risk.

Conclusions:

  • While established antihypertensive classes reduce stroke risk, individual efficacy varies.
  • Fixed-dose combinations of ACEI/ARB and CCB offer potential for better BP control.
  • Further clinical trials are necessary to confirm the efficacy of FDCs in primary stroke prevention.

Keywords:
antihypertensive therapyhypertensionpreventionrenin angiotensin systemstroke.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...